Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genzyme

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

Biogen Idec building

FDA approves Biogen Idec’s long-acting MS therapy

Plegridy gets US nod just weeks after EU approval

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

- PMLiVE

Sanofi ships synthetic malaria jab

French manufacturer says Gates Foundation-funded venture could widen treatment

- PMLiVE

Sanofi cuts $925m deal for MannKind’s inhaled insulin

French company bolsters diabetes business with Afrezza collaboration

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Sanofi reception

Sanofi asks Emcure to sell its cancer drugs in India

Will hand over marketing of Taxotere, Jevtana, Fludara and Fasturtec

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

Biogen Idec building

Plegridy approval underlines Biogen Idec’s dominance in MS

And Tecfidera boosts pharma company’s second quarter financial results

- PMLiVE

MS sailing challenge comes to UK

Oceans of Hope yacht has crew of people with multiple sclerosis and is supported by Biogen Idec

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links